Edgardo S. Santos, Vice President of Florida Society of Clinical Oncology and Medical Director of Broward County of Florida at The Oncology Institute of Hope and Innovation, shared a post on X:
”What have I learned after a great session of Immuno-Oncology (IO) in ESMO24? A great presentation by Dr. Reuss on biomarkers analysis from neoadjuvant Immuno-Oncology: the role of STK11, KEAP1, and SMARCA4 could be very important for patient selection in the future. Also, PCR after neoadjuvant is still not enough for cure.”
Source: Edgardo S. Santos/X